Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Valganciclovir - Roche

Drug Profile

Valganciclovir - Roche

Alternative Names: Cymeval; R127; RG 127; RO 1079070/194; RS 079070194; RS 79070; TA-9070; Valcyte; Valgancyclovir; Valixa

Latest Information Update: 06 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Developer Mitsubishi Tanabe Pharma Corporation; Roche; Stanford University School of Medicine; Vanderbilt University Medical Center
  • Class Antivirals; Hypoxanthines; Small molecules
  • Mechanism of Action Cytomegalovirus replication inhibitors; DNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cytomegalovirus retinitis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cytomegalovirus infections; Cytomegalovirus retinitis
  • No development reported Chronic fatigue syndrome
  • Discontinued Ulcerative colitis

Most Recent Events

  • 31 Aug 2018 Genentech and University of Utah initiates enrolment in the ValEAR phase III trial for Cytomegalovirus-infections (In infant) in USA (NCT03107871)
  • 24 Jun 2018 Biomarkers information updated
  • 28 Feb 2018 Mitsubhishi Tanabe Pharma files a public knowledge-based application for treatment of paediatric organ transplan patients with Cytomegalovirus infections (Prevention) in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top